Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27828902 | 0.84 | POLB (0.53) | POLBFFAR1FFAR4MEP1B | |
| SCHEMBL3967417 | 0.83 | POLB (0.48) | POLBFFAR1FFAR4 | |
| SCHEMBL31674134 | 0.79 | MEP1B (0.53) | POLBFFAR1FFAR4MEP1B | |
| SCHEMBL17743633 | 0.78 | POLB (0.49) | POLBFFAR1FFAR4 | |
| SCHEMBL4019177 | 0.77 | POLB (0.48) | POLBFFAR1FFAR4 | |
| SCHEMBL20234381 | 0.77 | MEP1B (0.50) | POLBFFAR1FFAR4MEP1B | |
| SCHEMBL32669390 | 0.76 | FFAR1 (0.50) | POLBFFAR1FFAR4 | |
| SCHEMBL11111891 | 0.76 | POLB (0.50) | POLBFFAR1FFAR4 | |
| SCHEMBL24362372 | 0.75 | MEP1B (0.48) | POLBFFAR1FFAR4MEP1B | |
| SCHEMBL30548827 | 0.75 | MEP1B (0.48) | POLBFFAR1FFAR4MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| EP-1640021-A1 | PREVENTIVE/REMEDY FOR URINARY DISTURBANCE | Takeda Pharmaceutical Company Limited (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20060041003-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1551820-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004026887-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | POLB 2519/4885FFAR1 3320/4885FFAR4 3949/4885 |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | POLB 1937/4885FFAR1 2179/4885FFAR4 3965/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | POLB 1937/4885FFAR1 2179/4885FFAR4 3965/4885 |
| US-20060041003-A1 | Estrogen receptor modulators | GPER1, ESR2, ESR1 | POLB 2794/4885FFAR1 197/4885FFAR4 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.